Related Experiment Videos
Follow-up study of tolmetin users
1Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Waltham, Massachusetts 02154.
Pharmacotherapy
|January 1, 1989
Summary
This study found no increased risk of allergic, blood, skin, or CNS events with tolmetin use. Hospitalizations for peptic ulcers were similar to other NSAIDs, with other risk factors present.
Area of Science:
- Pharmacology
- Clinical Research
- Drug Safety
Background:
- Tolmetin is a nonsteroidal anti-inflammatory drug (NSAID) used for various inflammatory conditions.
- Assessing the safety profile of commonly prescribed medications is crucial for patient care.
Observation:
- A cohort of 8,370 outpatients with over 24,000 tolmetin prescriptions was analyzed.
- Adverse events were tracked within 90 days of prescription or refill.
Findings:
- No hospital admissions were linked to acute allergic, blood, skin, or central nervous system events.
- Two cases of liver disease and two of nephrotic syndrome were noted, with an unlikely but unconfirmed link to tolmetin.
- Eleven patients were hospitalized for peptic ulcer disease; most had other contributing risk factors.
Implications:
- Tolmetin appears to have a low risk of severe acute adverse events.
- The risk of peptic ulcer disease with tolmetin is comparable to other NSAIDs and the general population.
- Further monitoring for gastrointestinal complications is warranted, especially in patients with risk factors.